StageZero Life Sciences Ltd
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers fr… Read more
StageZero Life Sciences Ltd (SZLSF) - Net Assets
Latest net assets as of September 2024: $-11.13 Million USD
Based on the latest financial reports, StageZero Life Sciences Ltd (SZLSF) has net assets worth $-11.13 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($580.75K) and total liabilities ($11.71 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-11.13 Million |
| % of Total Assets | -1915.8% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -530.58% |
| Growth Volatility | 519.21 |
StageZero Life Sciences Ltd - Net Assets Trend (1998–2022)
This chart illustrates how StageZero Life Sciences Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for StageZero Life Sciences Ltd (1998–2022)
The table below shows the annual net assets of StageZero Life Sciences Ltd from 1998 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $-7.50 Million | -371.69% |
| 2021-12-31 | $2.76 Million | +323.90% |
| 2020-12-31 | $-1.23 Million | +72.54% |
| 2019-12-31 | $-4.49 Million | +7.14% |
| 2018-12-31 | $-4.84 Million | -60.39% |
| 2017-12-31 | $-3.02 Million | +36.21% |
| 2016-12-31 | $-4.73 Million | -166.80% |
| 2015-12-31 | $-1.77 Million | -182.26% |
| 2014-12-31 | $2.15 Million | +23.63% |
| 2013-12-31 | $1.74 Million | -65.63% |
| 2012-12-31 | $5.07 Million | +1676.89% |
| 2011-12-31 | $-321.56K | -466.72% |
| 2010-12-31 | $87.69K | -96.48% |
| 2009-12-31 | $2.49 Million | +43.98% |
| 2008-12-31 | $1.73 Million | -87.48% |
| 2007-12-31 | $13.81 Million | -29.32% |
| 2006-12-31 | $19.54 Million | +229.49% |
| 2005-12-31 | $5.93 Million | -22.90% |
| 2004-12-31 | $7.69 Million | +34.00% |
| 2003-12-31 | $5.74 Million | +234.72% |
| 2002-12-31 | $1.71 Million | -26.05% |
| 2000-12-31 | $2.32 Million | -32.17% |
| 1999-12-31 | $3.42 Million | +1967.56% |
| 1998-12-31 | $165.36K | -- |
Equity Component Analysis
This analysis shows how different components contribute to StageZero Life Sciences Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12303005331.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $101.39 Million | % |
| Other Comprehensive Income | $1.23 Million | % |
| Other Components | $12.91 Million | % |
| Total Equity | $-7.50 Million | 100.00% |
StageZero Life Sciences Ltd Competitors by Market Cap
The table below lists competitors of StageZero Life Sciences Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
XMax Inc.
NASDAQ:XWIN
|
$61.78K |
|
Blackrock Innovation & Growth Trust
NYSE:BIGZ
|
$61.78K |
|
QuiaPEG Pharmaceuticals Holding AB
ST:QUIA
|
$61.82K |
|
Point of Care Nano-Technology Inc
PINK:PCNT
|
$61.86K |
|
KARO INVEST a.s.
PR:KARIN
|
$61.76K |
|
Gudeng Equipment Co., LTD.
TWO:6953
|
$61.69K |
|
Regenbogen AG
F:RGB
|
$61.68K |
|
KORAMCO The One REIT
KO:417310
|
$61.67K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in StageZero Life Sciences Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 2,761,765 to -7,503,337, a change of -10,265,102 (-371.7%).
- Net loss of 11,415,372 reduced equity.
- New share issuances of 1,542,548 increased equity.
- Other comprehensive income decreased equity by 70,714.
- Other factors decreased equity by 321,564.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-11.42 Million | -152.14% |
| Share Issuances | $1.54 Million | +20.56% |
| Other Comprehensive Income | $-70.71K | -0.94% |
| Other Changes | $-321.56K | -4.29% |
| Total Change | $- | -371.69% |
Book Value vs Market Value Analysis
This analysis compares StageZero Life Sciences Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-12-31 | $4.13 | $0.00 | x |
| 1999-12-31 | $17.74 | $0.00 | x |
| 2000-12-31 | $6.79 | $0.00 | x |
| 2002-12-31 | $3.45 | $0.00 | x |
| 2003-12-31 | $9.48 | $0.00 | x |
| 2004-12-31 | $9.77 | $0.00 | x |
| 2005-12-31 | $6.77 | $0.00 | x |
| 2006-12-31 | $17.93 | $0.00 | x |
| 2007-12-31 | $11.21 | $0.00 | x |
| 2008-12-31 | $1.40 | $0.00 | x |
| 2009-12-31 | $1.88 | $0.00 | x |
| 2010-12-31 | $0.06 | $0.00 | x |
| 2011-12-31 | $-0.17 | $0.00 | x |
| 2012-12-31 | $2.22 | $0.00 | x |
| 2013-12-31 | $0.41 | $0.00 | x |
| 2014-12-31 | $0.36 | $0.00 | x |
| 2015-12-31 | $-0.27 | $0.00 | x |
| 2016-12-31 | $-0.57 | $0.00 | x |
| 2017-12-31 | $-0.25 | $0.00 | x |
| 2018-12-31 | $-0.28 | $0.00 | x |
| 2019-12-31 | $-0.17 | $0.00 | x |
| 2020-12-31 | $-0.03 | $0.00 | x |
| 2021-12-31 | $0.04 | $0.00 | x |
| 2022-12-31 | $-0.08 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently StageZero Life Sciences Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -300.79%
- • Asset Turnover: 5.42x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-326.92%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | -3.74% | -950721.54% | 0.00x | 1.02x | $-22.72K |
| 1999 | -7.22% | -36825483.58% | 0.00x | 1.19x | $-588.62K |
| 2000 | -48.83% | -174217821.54% | 0.00x | 1.03x | $-1.36 Million |
| 2002 | -50.62% | -572.48% | 0.07x | 1.20x | $-1.04 Million |
| 2003 | -4.61% | -9.10% | 0.46x | 1.09x | $-838.35K |
| 2004 | -60.75% | -252.25% | 0.14x | 1.71x | $-5.44 Million |
| 2005 | -44.65% | -57.60% | 0.52x | 1.48x | $-3.24 Million |
| 2006 | -39.23% | -272.16% | 0.13x | 1.08x | $-9.62 Million |
| 2007 | -70.44% | -444.43% | 0.12x | 1.38x | $-11.11 Million |
| 2008 | -625.72% | -926.34% | 0.20x | 3.46x | $-11.00 Million |
| 2009 | -214.51% | -488.19% | 0.17x | 2.55x | $-5.59 Million |
| 2010 | -5490.81% | -2488.45% | 0.04x | 56.97x | $-4.82 Million |
| 2011 | 0.00% | -4445.35% | 0.02x | 0.00x | $-4.36 Million |
| 2012 | -100.18% | -1804.08% | 0.03x | 1.98x | $-5.59 Million |
| 2013 | -506.95% | -7120.02% | 0.04x | 1.72x | $-9.01 Million |
| 2014 | -306.83% | -312.89% | 0.72x | 1.36x | $-6.83 Million |
| 2015 | 0.00% | -1846.73% | 0.57x | 0.00x | $-5.84 Million |
| 2016 | 0.00% | -560.76% | 0.31x | 0.00x | $-5.44 Million |
| 2017 | 0.00% | -715.96% | 0.15x | 0.00x | $-2.65 Million |
| 2018 | 0.00% | -2121.82% | 0.07x | 0.00x | $-3.46 Million |
| 2019 | 0.00% | -2510.24% | 0.07x | 0.00x | $-3.03 Million |
| 2020 | 0.00% | -165.32% | 0.49x | 0.00x | $-6.74 Million |
| 2021 | -270.98% | -147.67% | 0.48x | 3.85x | $-7.76 Million |
| 2022 | 0.00% | -300.79% | 5.42x | 0.00x | $-10.67 Million |
Industry Comparison
This section compares StageZero Life Sciences Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| StageZero Life Sciences Ltd (SZLSF) | $-11.13 Million | -3.74% | N/A | $61.77K |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |